All In Biotech

Drug Trial Radar · NCT00134056

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients With Advanced Hormone Refractory Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Oct 27, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,038 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,038

Actual

Start

Aug 2006

Primary completion

Feb 2016

Study completion Feb 2016

Sponsor

Lead sponsor
SWOG Cancer Research NetworkResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Aug 24, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy, such as docetaxel, prednisone, and atrasentan work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether docetaxel, prednisone, and atrasentan are more effective than docetaxel and prednisone in treating prostate cancer. PURPOSE: This randomized phase III trial is studying docetaxel, prednisone, and atrasentan to see how well they work compared to docetaxel and prednisone in treating patients with stage IV prostate cancer and bone metastases that did not respond to previous hormone therapy.

Conditions

  • Metastatic Cancer
  • Prostate Cancer

Interventions

  • atrasentan hydrochlorideDrug

    Given orally

  • docetaxelDrug

    Docetaxel given IV and prednisone given orally

  • prednisoneDrug

    Docetaxel given IV and prednisone given orally

  • placeboOther

    Given orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compare Survival Between a Control or Standard Therapy Arm of Docetaxel + Placebo + Prednisone With Docetaxel + Atrasentan + Prednisone in Patients With Hormone Refractory Prostate Cancer.Time frame: Up to 7 years after study opens
  2. Compare Progression-free Survival Between a Control or Standard Therapy Arm of Docetaxel + Placebo + Prednisone With Docetaxel + Atrasentan + Prednisone in Patients With Hormone Refractory Prostate Cancer.Time frame: Up to 7 years after study opens

Locations

554 sites in 1 country. Site status is shown where the registry gives one.

  • Providence Cancer Center at Providence Hospital

    Mobile, Alabama

  • Alaska Regional Hospital Cancer Center

    Anchorage, Alaska

  • Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital

    Fairbanks, Alaska

  • Mayo Clinic Scottsdale

    Scottsdale, Arizona

  • Arizona Cancer Center at University of Arizona Health Sciences Center

    Tucson, Arizona

  • Hembree Mercy Cancer Center at St. Edward Mercy Medical Center

    Fort Smith, Arkansas

  • East Bay Radiation Oncology Center

    Castro Valley, California

  • Eden Medical Center

    Castro Valley, California

  • Valley Medical Oncology Consultants - Castro Valley

    Castro Valley, California

  • Valley Medical Oncology

    Fremont, California

  • Cancer Care Associates

    Fresno, California

  • Glendale Memorial Hospital Comprehensive Cancer Center

    Glendale, California

  • Rebecca and John Moores UCSD Cancer Center

    La Jolla, California

  • USC/Norris Comprehensive Cancer Center and Hospital

    Los Angeles, California

  • Contra Costa Regional Medical Center

    Martinez, California

  • Tibotec Therapeutics - Division of Ortho Biotech Products, LP

    Marysville, California

  • Community Hospital of the Monterey Peninsula Comprehensive Cancer Center

    Monterey, California

  • Camino Medical Group - Treatment Center

    Mountain View, California

  • El Camino Hospital Cancer Center

    Mountain View, California

  • Highland General Hospital

    Oakland, California

  • Alta Bates Summit Medical Center - Summit Campus

    Oakland, California

  • Bay Area Breast Surgeons, Incorporated

    Oakland, California

  • CCOP - Bay Area Tumor Institute

    Oakland, California

  • Larry G Strieff MD Medical Corporation

    Oakland, California

  • Tom K Lee, Incorporated

    Oakland, California

  • Desert Regional Medical Center Comprehensive Cancer Center

    Palm Springs, California

  • Palo Alto Medical Foundation

    Palo Alto, California

  • PCR Oncology

    Pismo Beach, California

  • Valley Care Medical Center

    Pleasanton, California

  • Valley Medical Oncology Consultants - Pleasanton

    Pleasanton, California

  • Lucy Curci Cancer Center at Eisenhower Memorial Hospital and Medical Center

    Rancho Mirage, California

  • University of California Davis Cancer Center

    Sacramento, California

  • Mercy General Hospital

    Sacramento, California

  • Salinas Valley Memorial Hospital

    Salinas, California

  • Doctors Medical Center - San Pablo Campus

    San Pablo, California

  • Tahoe Forest Cancer Center

    Truckee, California

  • Aurora Presbyterian Hospital

    Aurora, Colorado

  • University of Colorado Cancer Center at UC Health Sciences Center

    Aurora, Colorado

  • Boulder Community Hospital

    Boulder, Colorado

  • Penrose Cancer Center at Penrose Hospital

    Colorado Springs, Colorado

Showing 40 of 554 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.